Is MapLight Therapeutics, Inc. (MPLT) a buy?

MPLT currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.05x).

What is MapLight Therapeutics, Inc.'s quality score?

MPLT scores 36.179487179487175/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

EEDGAR/calls

Pulling SEC filings + quote and writing the call…

EEDGAR/calls

← New search

MPLT

MapLight Therapeutics, Inc.

Next earnings Sep 1, 2026 · consensus $-1.34 EPS

Last earnings -4.5% on 2026-05-14

Hold

$33.28

▲ +4.13%

$33.28▲ +81.46%

over 1Y

L $12.81EODHDH $33.28

Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand

Today+4.1%

1W+11.7%

1M+12.6%

3M+79.4%

YTD+98.4%

1Y+81.5%

Hold

Conviction

Horizon

Medium (3–12mo)

Street · 16 analysts

Buy

Conservative balance sheet (liabilities/equity 0.05x).

Return on equity -35.2% · latest

MapLight Therapeutics, Inc. shows limited reported revenue, and -35.2% ROE.

Financials · annual, by fiscal year

Line item	FY24	FY25
Revenue	—	—
Gross profit	—	—
Operating income	-$82.9M	-$169M
Net income	-$77.6M	-$161M
Diluted EPS	-$105.38	-$18.56
Net margin	—	—

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$1.37B

EV / EBITDA—

EV / Sales—

EV / FCF—

P / FCF—

PEG (trailing)—

Earnings yield-11.4%

FCF yield-9.8%

Quality & risk

ROIC (est.)-29.1%

Free cash flow-$139M

Total debt—

Net cash$46.7M

Capital returns

Buyback yield—

Dividend yield (est.)—

Shareholder yield—

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Insider activity

Form 4 · SEC

Last 90 days: 0 open-market buys · 6 sales

2026-06-23	Cox Troy Director	Award	7.86K
2026-06-23	Babler Martin Director	Award	7.86K
2026-06-23	Garnett Timothy John Director	Award	3.93K
2026-06-23	Luneborg Nanna Liebach Director	Award	3.93K
2026-06-23	Pavlov George Director	Award	3.93K
2026-06-23	Walker Maria C Director	Award	3.93K
2026-05-18	Kroeger Christopher A. Chief Executive Officer	Sell	118K @ $27.19	$3.21M
2026-05-18	Kroeger Christopher A. Chief Executive Officer	Sell	198.00 @ $28.15	$5.57K
2026-05-11	Hanson Kristopher General Counsel	Sell	284.00 @ $27.61	$7.84K
2026-05-11	Hanson Kristopher General Counsel	Sell	846.00 @ $28.70	$24.3K
2026-05-11	Hanson Kristopher General Counsel	Sell	6.98K @ $30.04	$210K
2026-05-11	Hanson Kristopher General Counsel	Sell	5.81K @ $30.56	$177K

Disclosure timeline

SEC · 8-Ks + reports

Some governance/structural items recently, but no outright red flags.

Earnings history

beat/miss · move

2026-05-14Miss -20.1% est▼ -4.50%8-K ↗

2026-03-26Miss -151.7% est▲ +6.01%8-K ↗

2026-01-09Miss -151.7% est▲ +4.83%8-K ↗

2025-12-04Miss -2013.1% est▲ +8.39%8-K ↗

Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.

Recent news

market news →

Weekly Buzz: IONS, MRK Get FDA Approvals; ACHV Gets CRL; ADCT Cuts Jobs; TECH AcquiredBullish

nasdaq.com· 2026-06-26

MapLight's ML-004 Misses Phase 2 Endpoint But Shows Irritability Signal In AdolescentsBearish

nasdaq.com· 2026-06-22

Pre-Market Movers: TNON, ADTX, LNAI See Sharp MovesBearish

nasdaq.com· 2026-06-22

MapLight Therapeutics Says IRIS Phase 2 Trial Did Not Meet Its Primary Endpoint; Stock Down 10.5%Bullish

nasdaq.com· 2026-06-22

Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug StumblesBullish

nasdaq.com· 2026-06-08

Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug StumblesBullish

finance.yahoo.com· 2026-06-08

Recent filings

all on EDGAR ↗

Quality score

Value—

GrowthF

ProfitabilityF

Financial healthB-

Momentum—

✗Profitable (positive net income)
✗Return on equity above 15%
✓Liabilities below 2× equity

Vs tracked universe

compare →

1043 tracked peers · median

EDGAR Score36 vs 67

Revenue growth— vs 7.1%

Net margin— vs 10.5%

Return on equity-35.2% vs 12.3%

P/E— vs 25.5

News sentiment

EODHD · 7d

Neutral

-0.01

vs typical · 13 articles

↑ improving

Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.

Revenue

—

Net margin

—

ROE

-35.2%

P/E

—

SEC fundamentals · FY 2025

■ revenue · ■ net income, by fiscal year

Net income-$161M-107.7%

Operating income-$169M-103.8%

Diluted EPS-$18.56+82.4%

Cash & equivalents$46.7M+22.2%

Total assets$480M+250.2%

Total liabilities$21.1M-2.7%

Stockholders' equity$458M+336.7%

L/E: 0.05x

Frequently asked

Is MapLight Therapeutics, Inc. (MPLT) a buy?: MPLT currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.05x).
What is MapLight Therapeutics, Inc.'s quality score?: MPLT scores 36.179487179487175/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0001770069, latest 10-Q filed 2026-05-14) · EODHD · as of 6/26/2026, 6:44:40 PM.

Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.